Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

1.475 +0.005 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,084
Open 1.475
Bid (Size) 1.420 (40)
Ask (Size) 1.440 (6)
Prev. Close 1.470
Today's Range 1.475 - 1.475
52wk Range 1.120 - 11.26
Shares Outstanding 54,642,580
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review. 
Via Benzinga

Performance

YTD
-85.82%
-85.82%
1 Month
-83.48%
-83.48%
3 Month
-85.42%
-85.42%
6 Month
-77.48%
-77.48%
1 Year
-82.38%
-82.38%

More News

Read More
The Latest Analyst Ratings For Marinus Pharma
Via Benzinga
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights
Via Benzinga
Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Are Stocks Up Today?
Via InvestorPlace
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
DJT Stock Alert: Trump Media Plunges on Share Sale Panic
Via InvestorPlace
Topics Government
Exposures Political
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Via InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
From Marinus Pharmaceuticals
Via Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 5, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.